OSE Immunotherapeutics: Cash position funded until end of 2026, results postponed
The Nantes-based biotech company published on September 28, 2026 its cash position as of June 30, 2026 and modified its financial calendar. It indicates it is continuing discussions with institutional investors in the United States and Europe with a view to extending its financing horizon.
Financing secured until end of December 2026
OSE Immunotherapeutics reported a cash position of 11.1 million euros as of June 30, 2026, compared to 17.0 million euros as of March 31, 2026. The company specifies that a flexible bridge financing in equity, implemented in May 2026, added to available cash, enables it to finance its activities until the end of December 2026 on the basis of current assumptions. This horizon does not include any potential milestone payments related to ongoing partnerships.
This bridge financing constitutes, according to the company, the first step of an overall strategy aimed at securing its three-year strategic plan. In this context, OSE Immunotherapeutics indicates it is continuing its interactions with institutional investors in order to extend its cash horizon beyond 2026. The company also specifies that it is evaluating several complementary options, including a possible new strategic partnership around one of its proprietary assets and a restructuring of its existing debt.
Postponement of half-yearly publication and clinical advances
As part of its financing efforts, the company has postponed to a later date the publication of its half-yearly financial results and its half-yearly financial report for 2026.
On the clinical front, recruitment for the phase 3 ARTEMIA study, evaluating Tedopi in 363 patients with metastatic non-small cell lung cancer, is progressing as planned and should be completed by the end of December 2026. The futility analysis, conditional upon the occurrence of a predefined number of events, was initially expected in the third quarter of 2026; as the study is reporting a lower number of deaths than initially predicted, this analysis is now expected in early 2027.
The company also indicates that the subcutaneous formulation of lusvertikimab should be validated by mid-2027, as initially planned, and mentions an opportunity to advance lusvertikimab in phase 2 in chronic pouchitis with the current intravenous formulation in 2027.
